clinical trials

NRx Pharmaceuticals appoints Prof. Joshua Brown, leading TMS researcher, as Chief Medical Innovation Officer to advance PTSD and depression treatments for veterans.

uniQure's $QURE stock crashes 49% after FDA rejects Huntington's gene therapy approval pathway; securities fraud lawsuit filed alleging misleading statements about regulatory expectations.

Pfizer's reasonable valuation, robust pipeline, and 6.4% dividend yield offer disciplined returns versus speculative biotech like Regencell, whose 21,000% surge lacks fundamental justification.

Exelixis secures FDA approval for zanzalintinib and expands beyond cabozantinib with robust pipeline, posting 57.9% EPS growth while advancing multiple Phase 3 trials.

Corcept Therapeutics faces securities lawsuit alleging misrepresentation of relacorilant clinical data and FDA approval prospects, while withholding known regulatory risks from investors.

ALX Oncology reduced losses and secured $150M in funding, extending cash runway to mid-2028. The company advances its clinical pipeline with CD47 biomarker validation for its cancer therapies.

Mesoblast reports strong H1 results with Ryoncil® revenue of $51.3M and narrowed net losses. Commercial expansion underway with 49 transplant centers operational and FY2026 guidance of $110-120M revenue.

Tevogen Bio pursues Sciometrix acquisition to integrate digital care management platform with its AI initiatives, aiming to become a revenue-generating healthcare enterprise.

BioLife Solutions achieved 29% revenue growth in 2025, reaching $96.2 million. The company expects 17-20% growth in 2026 and projects full-year profitability.

VivaVision Biotech rushes Hong Kong IPO as cash reserves dwindle to $5.2 million against $6.3 million quarterly burn rate. Two late-stage eye disease candidates drive investor appeal.

Vertex Pharmaceuticals outperforms Centessa with profitable cystic fibrosis revenue, successful product launches, and advanced pipeline, offering lower-risk investment profile versus pre-revenue competitor.

Great Point Partners expands Apogee Therapeutics stake to $28.23M, now its largest holding. Stock doubled in value; Phase 2 atopic dermatitis data expected mid-2026.

Eli Lilly strengthens obesity drug dominance as competitor's treatment fails trials and Lilly launches new monthly-dose Zepbound pen, commanding 60% market share.

Geron's RYTELO generated $184M in 2025 revenue. The company guides 2026 sales of $220-240M, driven by domestic expansion and international opportunities.

Immuron lifted H1 revenue 5% to AUD$4.2M with strong U.S. growth of 17%. The company secured AUD$7.3M funding and is pursuing partnerships to advance its clinical pipeline.

Day One Biopharmaceuticals reports 172% revenue growth to $155.4M, driven by OJEMDA sales strength. Company acquires Mersana Therapeutics to expand pipeline.

Cytokinetics launches MYQORZO for heart disease post-FDA approval; guides $830-870M spending in 2026 with strong cash position supporting commercial expansion.

Commodore Capital cuts $84M Nuvalent stake to 3.68% despite 29% stock gains. Biotech firm awaits September PDUFA decision for lead drug candidate.

Iovance's newly approved melanoma therapy Amtagvi generated $68M in quarterly revenue with strong 52% response rates, positioning the biotech for pipeline expansion across multiple cancer indications.

Eupraxia Pharmaceuticals raises $63.2M to advance its GI disease pipeline, including EP-104GI trials for eosinophilic esophagitis and other gastrointestinal indications.